Effect of Remimazolam and Propofol on Postoperative Delirium
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general
anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly
metabolized by tissue esterase that it does not accumulate even after infusion for long
periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also,
hemodynamic stability compared to propofol gives clinicians preference to use for geriatric
anesthesia. However, the study on the effect of remimazolam compared to propofol on
postoperative delirium have not been carried out. The purpose of the study is to compare the
incidence of postoperative delirium and recovery profile in elderly patients undergoing
orthopedic surgery using either remimazolam or propofol.